Effect of palmitoylethanolamide–polydatin combination on chronic pelvic pain associated with endometriosis: Preliminary observations

Ugo Indraccolo, Fabrizio Barbieri, F Barbieri
European journal of obstetrics, gynecology, and reproductive biology · 2010 · vol. 150(1) , pp. 76–79 · doi:10.1016/j.ejogrb.2010.01.008 · PMID:20176435 · W2001078159
article OA: closed CC0 ⤵ 24 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This preliminary study observed the effect of a palmitoylethanolamide–polydatin combination on chronic pelvic pain in women with endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

mesh:D004414mesh:D004715mesh:D017699endometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Glucosides Palmitic Acids Pelvic Pain Stilbenes Adult Amides Drug Combinations Dyspareunia Dyspareunia Endocannabinoids Endometriosis Endometriosis Ethanolamines Female Glucosides Humans Mast Cells Mast Cells Middle Aged

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Cited by (24)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:18.915199+00:00
License: CC0 · commercial use OK